文献速递核素与放射性配体治疗肿瘤 PET/CT

长效生长抑素类似物[225Ac]Ac-EBTATE抗小细胞肺癌与胰腺神经内分泌肿瘤的临床前安全性与有效性

Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-04

在健康BALB/c小鼠及荷瘤裸鼠中评估[225Ac]Ac-EBTATE的药代动力学、生物分布与安全性,并开展放射性配体治疗。该药物在SSTR2阳性小细胞肺癌与胰腺神经内分泌肿瘤模型中显示安全性和有效性,作者认为值得临床研究。

要点

  • 药代动力学显示清除半衰期为40.27 ± 9.23 h,健康雄雌BALB/c小鼠生物分布相似,血液循环延长并于6 h达峰。
  • 2 × 34 kBq、间隔10天给药在健康BALB/c小鼠中总体耐受28天。
  • 2 × 30 kBq、间隔10天给药使NCI-H524与QGP1.SSTR2模型生存率达100%,完全缓解率分别为80%与20%。

核心结论

  • [225Ac]Ac-EBTATE对SSTR2阳性小细胞肺癌和胰腺神经内分泌肿瘤安全有效,因此值得开展临床研究。

研究设计与样本

  • 在健康雌性和/或雄性BALB/c小鼠静脉注射[225Ac]Ac-EBTATE后评估药代动力学、生物分布和安全性。
  • 在雌性无胸腺BALB/c裸鼠的皮下小细胞肺癌模型NCI-H524(高表达SSTR2)和NCI-H727(低表达SSTR2)以及胰腺神经内分泌肿瘤模型QGP1.SSTR2中进一步研究生物分布和放射性配体治疗。

主要发现

  • 药代动力学证实清除半衰期为40.27 ± 9.23 h,健康雄雌BALB/c小鼠生物分布相似,血液循环延长并于6 h达峰。
  • NCI-H524和NCI-H727皮下异种移植模型的生物分布显示,SSTR2过表达时肿瘤摄取一致,男性和女性的预估人体有效剂量分别为61.7和83.7毫希沃特/兆贝可。
  • 间隔10天给予2 × 34 kBq的[225Ac]Ac-EBTATE在健康BALB/c小鼠中总体耐受28天,经血液生化、全血细胞计数和H&E染色器官组织病理学检查评估。
  • 间隔10天给予2 × 30 kBq的[225Ac]Ac-EBTATE靶向α治疗使NCI-H524和QGP1.SSTR2模型生存率达100%,完全缓解率分别为80%和20%。
  • [225Ac]Ac-EBTATE在NCI-H727模型中呈剂量依赖性反应,2 × 30 kBq组和2 × 15 kBq组的中位生存期分别为63天(p < 0.0007)和47天(p = 0.0148)。

关键数值与推荐

  • 健康BALB/c小鼠中间隔10天给予2 × 34 kBq的[225Ac]Ac-EBTATE,总体耐受28天。
  • 荷瘤模型中间隔10天给予2 × 30 kBq的[225Ac]Ac-EBTATE,NCI-H524和QGP1.SSTR2模型的完全缓解率分别为80%和20%。
  • NCI-H727模型中2 × 30 kBq组中位生存期63天(p < 0.0007),2 × 15 kBq组47天(p = 0.0148)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report the preclinical evaluation of potent long-acting [225Ac]Ac-EBTATE against SSTR2-positive small cell lung cancer (SCLC) and pancreatic neuroendocrine tumors (pan-NETs). METHODS: The pharmacokinetic, biodistribution, and safety studies were evaluated in healthy female and/or male BALB/c mice after intravenous injections of [225Ac]Ac-EBTATE. Further biodistribution and radioligand therapy were investigated in female athymic BALB/c nude mice bearing high or low SSTR2-expressing subcutaneous SCLC models NCI-H524 or NCI-H727, respectively, and in a pan-NET model QGP1.SSTR2. RESULTS: Pharmacokinetics confirmed a prolonged clearance half-life (40.27 ± 9.23 h) while biodistribution in healthy male and female BALB/c mice was similar, with prolonged blood circulation that peaked at 6 h. Biodistribution in subcutaneous xenograft models of NCI-H524 and NCI-H727 showed consistent tumor-uptake with SSTR2-overexpression while the projected human effective doses for males and females were 61.7 and 83.7 millisievert/megabecquerel, respectively. 2 × 34 kBq of [225Ac]Ac-EBTATE administered 10 days (d) apart, was generally tolerated for 28 days in healthy BALB/c mice as revealed by blood biochemistry, complete blood count, and histopathological examination of H&E-stained organs. Targeted alpha therapy at 2 × 30 kBq of [225Ac]Ac-EBTATE, injected 10 days apart, resulted in 100% survivals and 80% and 20% complete remissions for NCI-H524 and QGP1.SSTR2 models, respectively. Additionally, [225Ac]Ac-EBTATE had a dose-dependent response in the NCI-H727 model, with median survivals for 2 × 30 kBq and 2 × 15 kBq groups being 63 d (p < 0.0007), and 47 d (p = 0.0148), respectively. CONCLUSIONS: [225Ac]Ac-EBTATE is safe and effective against SCLC and pan-NET and therefore warrants clinical investigation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Njotu FN, Pougoue Ketchemen J, Babeker H, et al. Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2024. PMID: 39627348. doi:10.1007/s00259-024-07011-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。